Cancer is one of the leading causes of mortality amongst world's population, in which
prostate cancer is one of the most encountered malignancies among men. Globally, it is the …

Over the past few years, we have developed an increased understanding of the molecular
mechanisms that underlie prostate cancer progression and castration resistance and …

The clinical success of anticancer therapy is usually limited by drug resistance and the
metastatic dissemination of cancer cells. Mitochondria are essential generators of cellular …

We studied mechanisms of resistance to the novel taxane cabazitaxel in established cellular
models of taxane resistance. We also developed cabazitaxel-resistant variants from MCF-7 …

The translation of nanoparticles (NPs) from laboratory to clinical settings is limited, which is
not ideal. One of the reasons for this is that we currently have limited ability to precisely …

Herein, ferumoxytol (Fer) capped antiprogrammed cell death‐ligand 1 (PD‐L1) antibodies
(aPD‐L1) loaded ultralarge pore mesoporous silica nanoparticles (Fer‐ICB‐UPMSNPs) are …

Purpose: Patients with luminal breast cancer (LBC) often become endocrine resistant over
time. We investigated the molecular changes associated with acquired hormonoresistances …

Prostate cancer is the most common cancer in men, with an incidence that is expected to
increase in the coming years. Prostate cancer is usually diagnosed in men> 65 years of age …

Background The optimal therapeutic strategies for patients with metastatic hormone-
sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer …

Nanomedicines have achieved several successful clinical applications for cancer therapy
over the past decades. To date, numerous nanomedicine formats and design rationales …